Mark G Kris
Overview
Explore the profile of Mark G Kris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
342
Citations
30470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cooper A, Arfe A, Ricciuti B, Gagne A, Sholl L, Di Federico A, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100759.
PMID: 39802817
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical,...
2.
Gormally M, Chen M, Noronha A, Panageas K, Reynolds M, Kohlasch K, et al.
JAMA Oncol
. 2024 Nov;
11(1):74-76.
PMID: 39602136
No abstract available.
3.
Zhao B, Dercle L, Yang H, Riely G, Kris M, Schwartz L
Sci Data
. 2024 Nov;
11(1):1259.
PMID: 39567508
Quantitative imaging biomarkers (QIB) are increasingly used in clinical research to advance precision medicine approaches in oncology. Computed tomography (CT) is a modality of choice for cancer diagnosis, prognosis, and...
4.
Liu S, Erazo T, Jee J, Arfe A, Gupta A, Pike L, et al.
Eur J Cancer
. 2024 Aug;
210:114257.
PMID: 39151324
Introduction: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting....
5.
Chen M, Yang S, Tao J, Desilets A, Diamond E, Wilhelm C, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3812-3823.
PMID: 38922339
Purpose: Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course. Experimental Design: We collected data...
6.
Spicer J, Cascone T, Wynes M, Ahn M, Dacic S, Felip E, et al.
J Thorac Oncol
. 2024 Jun;
19(10):1373-1414.
PMID: 38901648
Advances in the multidisciplinary care of early stage resectable NSCLC (rNSCLC) are emerging at an unprecedented pace. Numerous phase 3 trials produced results that have transformed patient outcomes for the...
7.
Deep learning of cell spatial organizations identifies clinically relevant insights in tissue images
Wang S, Rong R, Zhou Q, Yang D, Zhang X, Zhan X, et al.
Nat Commun
. 2023 Dec;
14(1):7872.
PMID: 38081823
Recent advancements in tissue imaging techniques have facilitated the visualization and identification of various cell types within physiological and pathological contexts. Despite the emergence of cell-cell interaction studies, there is...
8.
Dacic S, Travis W, Giltnane J, Kos F, Abel J, Hilz S, et al.
J Thorac Oncol
. 2023 Dec;
19(5):719-731.
PMID: 38070597
Introduction: Pathologic response (PathR) by histopathologic assessment of resected specimens may be an early clinical end point associated with long-term outcomes with neoadjuvant therapy. Digital pathology may improve the efficiency...
9.
Chaft J, Oezkan F, Kris M, Bunn P, Wistuba I, Kwiatkowski D, et al.
Nat Med
. 2023 Oct;
30(1):303.
PMID: 37816821
No abstract available.
10.
Lebow E, Shaverdian N, Eichholz J, Kratochvil L, McCune M, Murciano-Goroff Y, et al.
Front Oncol
. 2023 Oct;
13:1253629.
PMID: 37795442
Background: Sensitive and reliable biomarkers for early detection of recurrence are needed to improve post-definitive radiation risk stratification, disease management, and outcomes for patients with unresectable early-stage or locally advanced...